Y-mAbs Therapeutics Inc (YMAB)
13.80
-3.44
(-19.95%)
USD |
NASDAQ |
May 08, 10:40
Y-mAbs Therapeutics Gross Profit Margin (Quarterly): 91.27% for Dec. 31, 2023
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 91.27% |
September 30, 2023 | 87.07% |
June 30, 2023 | 77.60% |
March 31, 2023 | 89.71% |
December 31, 2022 | 93.58% |
September 30, 2022 | 80.26% |
June 30, 2022 | 88.52% |
Date | Value |
---|---|
March 31, 2022 | 82.54% |
December 31, 2021 | 84.78% |
September 30, 2021 | 93.86% |
June 30, 2021 | 96.26% |
March 31, 2021 | 98.27% |
December 31, 2020 | 89.38% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
77.60%
Minimum
Jun 2023
98.27%
Maximum
Mar 2021
88.70%
Average
89.38%
Median
Dec 2020
Gross Profit Margin (Quarterly) Benchmarks
The Cooper Companies Inc | 66.96% |
Puma Biotechnology Inc | 75.49% |
Humacyte Inc | -- |
Moderna Inc | 42.52% |
NovaBay Pharmaceuticals Inc | 48.70% |
Gross Profit Margin (Quarterly) Related Metrics
Return on Equity | -20.49% |
Return on Assets | -16.04% |
Return on Invested Capital | -20.49% |
Profit Margin (Quarterly) | -4.23% |
Operating Margin (Quarterly) | -13.69% |
Return on Net Operating Assets | -72.37% |